CURE

FDA Fast Tracks ITM-94 For Clear Cell Renal Cell Carcinoma Diagnosis

The FDA's fast track designation aims to expedite ITM-94's development for diagnosing clear cell renal cell carcinoma. The FDA has granted fast track designation to ITM-94 as a diagnostic agent for ...
Morningstar

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global ...
ascopubs.org

Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma: 1 year updated results from UC-001, a single-center, single-arm, phase II ...

Comparison of 68Ga-NY104 PET/CT with 18F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, comparative phase II study. This is an ASCO Meeting Abstract ...
Oncology Nurse Advisor

Nivolumab Administered Subcutaneously, Intravenously Have Similar ccRCC Outcomes

Results of the CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in renal cell carcinoma, were presented at JADPRO 2025.
12 NEWS

3 Doors Down lead singer Brad Arnold reveals cancer diagnosis, cancels tour

The lead singer shared the news in a heartfelt video message Wednesday. In the roughly minute-long Instagramvideo, Arnold shared that he was diagnosed with clear cell renal cell carcinoma, a common ...
ascopubs.org

Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic ...

Who undergoes cytoreductive nephrectomy now? An analysis of perioperative risk characteristics in contemporary patients. Comparison of IO-TKI vs IO-IO combinations in IMDC poor-risk metastatic renal ...